EyePoint's DURAVYU Phase 3 Wet AMD Trials Receive Third Positive DSMC Recommendation

summarizeSummary

EyePoint, Inc. announced its third consecutive positive recommendation from the Data Safety Monitoring Committee for its pivotal Phase 3 DURAVYU program for wet AMD, reinforcing confidence ahead of mid-2026 topline data.

check_boxKey Events

• Third Positive DSMC Recommendation

  The independent Data Safety Monitoring Committee (DSMC) issued its third consecutive positive recommendation for EyePoint's pivotal Phase 3 program evaluating DURAVYU for wet age-related macular degeneration (wet AMD).

• Trials to Continue as Planned

  The DSMC recommended that both the LUGANO and LUCIA trials continue as planned with no protocol modifications, indicating no significant safety concerns.

• Favorable Safety Profile Confirmed

  Interim masked safety data from the Phase 3 trials show a continued favorable safety profile for DURAVYU, consistent with safety observed in four previously completed clinical trials.

• Progress Towards Topline Data

  All active patients in the treatment arm have reached their second DURAVYU dose, with over 35% receiving a third dose. Topline data for the LUGANO trial is on track for mid-2026, with LUCIA to follow shortly after.

auto_awesomeAnalysis

This 8-K reports a critical de-risking event for EyePoint's lead product candidate, DURAVYU, which is in pivotal Phase 3 trials for wet AMD. The third consecutive positive recommendation from the independent Data Safety Monitoring Committee (DSMC) confirms the safety profile and integrity of the trials, reducing the risk of unexpected setbacks. For a clinical-stage biopharmaceutical company, successful progression of late-stage clinical trials is paramount, especially given recent financial losses. This news builds significant confidence as the company approaches the crucial mid-2026 topline data readout, which will determine the drug's potential for market approval.